Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/36234
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorMARANHAO, Raul C.
dc.contributor.authorPALA, Daniela
dc.contributor.authorFREITAS, Fatima R.
dc.date.accessioned2020-06-01T15:01:34Z-
dc.date.available2020-06-01T15:01:34Z-
dc.date.issued2020
dc.identifier.citationCURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, v.27, n.2, p.104-109, 2020
dc.identifier.issn1752-296X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/36234-
dc.description.abstractPurpose of review The speed of removal from the plasma of apolipoprotein B-containing lipoproteins, for example, chylomicrons, VLDL and LDL is determinant of the plasma concentration of these lipoproteins, is influenced by genetic features and ambient factors, and has implications in atherogenesis. As aging increases the clinical complications of atherosclerosis, it is important to appraise the status of the removal mechanisms in elderly individuals. Recent findings Removal of triglyceride-rich lipoproteins remnants is delayed but the triglyceride breakdown is unchanged in elderly individuals. The discovery of PCSK9, enzyme that degrades LDL receptors, and the recent observation that PCSK9 is elevated in the elderly raises another hypothesis to account for the increased LDL-cholesterol levels in the elderly. The removal of cholesterol from cells by HDL, the first step of cholesterol reverse transport is also less efficient in the elderly, which may compromise the body cholesterol homeostasis. Aging determines reduction of the efficiency of lipoprotein plasma removal mechanisms, which is implicated in increased incidence of cardia complications. Moreover, aging is frequently accompanied by physical activity reduction, weight gain, and metabolic disturbances that can further decrease the efficacy of the removal mechanisms. This knowledge is important for promoting cardiovascular health in the elderly and prolonging survival.eng
dc.description.sponsorshipSao Paulo Research Foundation (Fapesp, Brazil)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
dc.description.sponsorshipNational Institute of Science and Technology Complex Fluids (INCT-FCx, Brazil)
dc.description.sponsorshipNational Council for Scientific and Technological Development (CNPq, Brasilia, Brazil)National Council for Scientific and Technological Development (CNPq)
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINSeng
dc.relation.ispartofCurrent Opinion in Endocrinology Diabetes and Obesity
dc.rightsrestrictedAccesseng
dc.subjectcholesteroleng
dc.subjectemulsionseng
dc.subjectlow-density lipoprotein receptors and agingeng
dc.subjectlipoprotein kineticseng
dc.subjecttriglycerideseng
dc.subject.otherlow-density-lipoproteineng
dc.subject.otherchylomicron-like emulsioneng
dc.subject.othersubtilisin/kexin type 9eng
dc.subject.otherdisease risk-factorseng
dc.subject.otherall-cause mortalityeng
dc.subject.otherplasma kineticseng
dc.subject.othermonoclonal-antibodyeng
dc.subject.otherdiabetes-mellituseng
dc.subject.othertotal cholesteroleng
dc.subject.otherlipid-metabolismeng
dc.titleLipoprotein removal mechanisms and aging: implications for the cardiovascular health of the elderlyeng
dc.typearticleeng
dc.rights.holderCopyright LIPPINCOTT WILLIAMS & WILKINSeng
dc.identifier.doi10.1097/MED.0000000000000529
dc.identifier.pmid32011347
dc.subject.wosEndocrinology & Metabolismeng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
hcfmusp.author.externalPALA, Daniela:Univ Sao Paulo, Hosp Clin HCFMUSP, Inst Coracao InCor, Fac Med, Av Dr Eneas de Carvalho Aguiar,44 Bloco 2, BR-05403000 Sao Paulo, Brazil
hcfmusp.description.beginpage104
hcfmusp.description.endpage109
hcfmusp.description.issue2
hcfmusp.description.volume27
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000524528300004
hcfmusp.origem.id2-s2.0-85080854993
hcfmusp.publisher.cityPHILADELPHIAeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceAbbott RD, 1998, AM J CARDIOL, V82, P172, DOI 10.1016/S0002-9149(98)00310-5eng
hcfmusp.relation.referenceAnagnostis P, 2015, MATURITAS, V81, P62, DOI 10.1016/j.maturitas.2015.02.262eng
hcfmusp.relation.referenceBaass A, 2009, CLIN CHEM, V55, P1637, DOI 10.1373/clinchem.2009.126987eng
hcfmusp.relation.referenceBenjo AM, 2006, ATHEROSCLEROSIS, V187, P116, DOI 10.1016/j.atherosclerosis.2005.08.025eng
hcfmusp.relation.referenceBerenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302eng
hcfmusp.relation.referenceBerrougui H, 2007, J LIPID RES, V48, P328, DOI 10.1194/jlr.M600167-JLR200eng
hcfmusp.relation.referenceBerrougui H, 2009, REJUV RES, V12, P117, DOI 10.1089/rej.2008.0840eng
hcfmusp.relation.referenceBey L, 2001, J APPL PHYSIOL, V91, P687eng
hcfmusp.relation.referenceBRODOWS RG, 1972, NEW ENGL J MED, V287, P969, DOI 10.1056/NEJM197211092871907eng
hcfmusp.relation.referenceChyou PH, 2000, AGE AGEING, V29, P69, DOI 10.1093/ageing/29.1.69eng
hcfmusp.relation.referenceCOHN JS, 1988, J LIPID RES, V29, P469eng
hcfmusp.relation.referenceCui Q, 2010, ATHEROSCLEROSIS, V213, P632, DOI 10.1016/j.atherosclerosis.2010.09.027eng
hcfmusp.relation.referenceDesai NR, 2013, CIRCULATION, V128, P962, DOI 10.1161/CIRCULATIONAHA.113.001969eng
hcfmusp.relation.referenceDi Pietro N, 2016, VASC PHARMACOL, V84, P1, DOI 10.1016/j.vph.2016.05.013eng
hcfmusp.relation.referenceEbtehaj S, 2019, ARTERIOSCL THROM VAS, V39, P1874, DOI 10.1161/ATVBAHA.119.312645eng
hcfmusp.relation.referenceEnkhmaa B, 2016, J LIPID RES, V57, P1111, DOI 10.1194/jlr.R051904eng
hcfmusp.relation.referenceERICSSON S, 1991, J CLIN INVEST, V87, P591, DOI 10.1172/JCI115034eng
hcfmusp.relation.referenceField PA, 2000, METABOLISM, V49, P492, DOI 10.1016/S0026-0495(00)80014-1eng
hcfmusp.relation.referenceFogelstrand P, 2012, NUTR METAB CARDIOVAS, V22, P1, DOI 10.1016/j.numecd.2011.09.007eng
hcfmusp.relation.referenceGillard BK, 2018, J CLIN LIPIDOL, V12, P849, DOI 10.1016/j.jacl.2018.04.001eng
hcfmusp.relation.referenceHong Young Mi, 2010, Korean Circ J, V40, P1, DOI 10.4070/kcj.2010.40.1.1eng
hcfmusp.relation.referenceHUBERT HB, 1987, AM J EPIDEMIOL, V125, P812, DOI 10.1093/oxfordjournals.aje.a114598eng
hcfmusp.relation.referenceJackson KG, 2003, CLIN SCI, V105, P457, DOI 10.1042/CS20030134eng
hcfmusp.relation.referenceJellinger PS, 2017, ENDOCR PRACT, V23, P479, DOI 10.4158/EP171764.GLeng
hcfmusp.relation.referenceJulve J, 2016, CLIN CHIM ACTA, V455, P134, DOI 10.1016/j.cca.2016.02.004eng
hcfmusp.relation.referenceKarpe F, 1997, DIABETIC MED, V14, pS60, DOI 10.1002/(SICI)1096-9136(199708)14:3+<S60::AID-DIA447>3.3.CO;2-Meng
hcfmusp.relation.referenceKarpe F, 1999, METABOLISM, V48, P301, DOI 10.1016/S0026-0495(99)90076-8eng
hcfmusp.relation.referenceKhera AV, 2015, AM J CARDIOL, V115, P178, DOI 10.1016/j.amjcard.2014.10.018eng
hcfmusp.relation.referenceKORTLANDT W, 1992, DIABETOLOGIA, V35, P202, DOI 10.1007/BF00400918eng
hcfmusp.relation.referenceKRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335eng
hcfmusp.relation.referenceLibby P, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0116-x, 10.1038/s41572-019-0106-z]eng
hcfmusp.relation.referenceLin XL, 2018, BIOMED PHARMACOTHER, V104, P36, DOI 10.1016/j.biopha.2018.05.024eng
hcfmusp.relation.referenceLoh TP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162102eng
hcfmusp.relation.referenceLusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203eng
hcfmusp.relation.referenceMangili OC, 2014, ATHEROSCLEROSIS, V233, P319, DOI 10.1016/j.atherosclerosis.2013.12.008eng
hcfmusp.relation.referenceMaranhao RC, 2014, ARQ BRAS CARDIOL, V103, P76, DOI 10.5935/abc.20140101eng
hcfmusp.relation.referenceMaranhao RC, 1996, ATHEROSCLEROSIS, V126, P15, DOI 10.1016/0021-9150(96)05889-3eng
hcfmusp.relation.referenceMARTINS MCT, 1995, BRAZ J MED BIOL RES, V28, P427eng
hcfmusp.relation.referenceMayne J, 2008, LIPIDS HEALTH DIS, V7, DOI 10.1186/1476-511X-7-22eng
hcfmusp.relation.referenceMc Auley MT, 2014, EXPERT REV ENDOCRINO, V9, P357, DOI 10.1586/17446651.2014.921569eng
hcfmusp.relation.referenceMc Auley Mark Tomas, 2018, Subcell Biochem, V90, P99, DOI 10.1007/978-981-13-2835-0_4eng
hcfmusp.relation.referenceMcCormick SPA, 2019, PATHOLOGY, V51, P155, DOI 10.1016/j.pathol.2018.11.003eng
hcfmusp.relation.referenceMelendez QM, 2017, BIOCHEM BIOPH RES CO, V492, P103, DOI 10.1016/j.bbrc.2017.08.026eng
hcfmusp.relation.referenceMero N, 2000, ATHEROSCLEROSIS, V150, P167, DOI 10.1016/S0021-9150(99)00364-0eng
hcfmusp.relation.referenceMichos ED, 2019, NEW ENGL J MED, V381, P1557, DOI 10.1056/NEJMra1806939eng
hcfmusp.relation.referenceMilan AM, 2016, BRIT J NUTR, V115, P791, DOI 10.1017/S000711451500505Xeng
hcfmusp.relation.referenceMILLAR JS, 1995, J LIPID RES, V36, P1155eng
hcfmusp.relation.referenceMurakata Y, 2015, BIOMED REP, V3, P767, DOI 10.3892/br.2015.505eng
hcfmusp.relation.referenceNakajima K, 2018, CURR OPIN ENDOCRINOL, V25, P108, DOI 10.1097/MED.0000000000000393eng
hcfmusp.relation.referenceNEWSCHAFFER CJ, 1992, AM J EPIDEMIOL, V136, P23, DOI 10.1093/oxfordjournals.aje.a116417eng
hcfmusp.relation.referenceLe NA, 2015, LIPIDS, V50, P447, DOI 10.1007/s11745-015-4005-0eng
hcfmusp.relation.referenceOrth M, 2003, CLIN CHEM LAB MED, V41, P652, DOI 10.1515/CCLM.2003.099eng
hcfmusp.relation.referencePallottini V, 2006, J CELL BIOCHEM, V98, P1044, DOI 10.1002/jcb.20951eng
hcfmusp.relation.referenceParhofer KG, 2000, J CLIN ENDOCR METAB, V85, P4224, DOI 10.1210/jc.85.11.4224eng
hcfmusp.relation.referencePatel KM, 2015, CIRC RES, V116, P789, DOI 10.1161/CIRCRESAHA.116.305811eng
hcfmusp.relation.referencePinto LB, 2001, LIPIDS, V36, P1307, DOI 10.1007/s11745-001-0845-yeng
hcfmusp.relation.referencePirillo A, 2019, CURR MED CHEM, V26, P1644, DOI 10.2174/0929867325666180530110543eng
hcfmusp.relation.referenceRaal FJ, 2016, J LIPID RES, V57, P1086, DOI 10.1194/jlr.P065334eng
hcfmusp.relation.referenceRaal FJ, 2014, J AM COLL CARDIOL, V63, P1278, DOI 10.1016/j.jacc.2014.01.006eng
hcfmusp.relation.referenceRedgrave TG, 2004, BIOCHEM SOC T, V32, P79, DOI 10.1042/BST0320079eng
hcfmusp.relation.referenceRelas H, 2000, J GERONTOL A-BIOL, V55, pB515, DOI 10.1093/gerona/55.11.B515eng
hcfmusp.relation.referenceRohatgi A, 2014, NEW ENGL J MED, V371, P2383, DOI 10.1056/NEJMoa1409065eng
hcfmusp.relation.referenceRohrer L, 2004, CURR OPIN LIPIDOL, V15, P269, DOI 10.1097/00041433-200406000-00006eng
hcfmusp.relation.referenceRomagnuolo R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180869eng
hcfmusp.relation.referenceRomagnuolo R, 2015, J BIOL CHEM, V290, P11649, DOI 10.1074/jbc.M114.611988eng
hcfmusp.relation.referenceRuscica M, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005764eng
hcfmusp.relation.referenceSaeed A, 2018, FRONT BIOSCI-LANDMRK, V23, P1099, DOI 10.2741/4635eng
hcfmusp.relation.referenceSantos RD, 2005, LIPIDS, V40, P737, DOI 10.1007/s11745-005-1437-6eng
hcfmusp.relation.referenceSantos RD, 2000, AM J CARDIOL, V85, P1163, DOI 10.1016/S0002-9149(00)00721-9eng
hcfmusp.relation.referenceSASAKI J, 1982, BIOCHIM BIOPHYS ACTA, V713, P199, DOI 10.1016/0005-2760(82)90237-5eng
hcfmusp.relation.referenceSegatto M, 2011, J CELL PHYSIOL, V226, P2610, DOI 10.1002/jcp.22607eng
hcfmusp.relation.referenceShapiro MD, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.010932eng
hcfmusp.relation.referenceSigala F, 2018, CURR OPIN PHARMACOL, V39, P9, DOI 10.1016/j.coph.2017.11.010eng
hcfmusp.relation.referenceSniderman AD, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003665eng
hcfmusp.relation.referenceSniderman AD, 2016, JAMA CARDIOL, V1, P492, DOI 10.1001/jamacardio.2016.0991eng
hcfmusp.relation.referenceSposito AC, 2004, ATHEROSCLEROSIS, V176, P397, DOI 10.1016/j.atherosclerosis.2004.05.023eng
hcfmusp.relation.referenceSposito AC, 2003, ATHEROSCLEROSIS, V166, P311, DOI 10.1016/S0021-9150(02)00334-9eng
hcfmusp.relation.referenceSposito AC, 2002, ATHEROSCLEROSIS, V161, P447, DOI 10.1016/S0021-9150(01)00661-Xeng
hcfmusp.relation.referenceStrong A, 2012, J CLIN INVEST, V122, P2807, DOI 10.1172/JCI63563eng
hcfmusp.relation.referenceTruesdale KP, 2007, AM J EPIDEMIOL, V165, P890, DOI 10.1093/aje/kwk072eng
hcfmusp.relation.referencevan Wijk JPH, 2005, ATHEROSCLEROSIS, V178, P147, DOI 10.1016/j.atherosclerosis.2004.08.009eng
hcfmusp.relation.referenceVinagre CG, 2018, AGING DIS, V9, P748, DOI 10.14336/AD.2017.1003eng
hcfmusp.relation.referenceVinagre CGC, 2007, J APPL PHYSIOL, V103, P1166, DOI 10.1152/japplphysiol.01176.2006eng
hcfmusp.relation.referenceWeintraub MS, 1996, BRIT MED J, V312, P935, DOI 10.1136/bmj.312.7036.935eng
hcfmusp.relation.referenceWILSON PWF, 1994, J GERONTOL, V49, pM252, DOI 10.1093/geronj/49.6.M252eng
hcfmusp.relation.referenceWong MWK, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214141eng
dc.description.indexMEDLINEeng
dc.identifier.eissn1752-2978
hcfmusp.citation.scopus1-
hcfmusp.scopus.lastupdate2022-07-08-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - HC/InCor
Instituto do Coração - HC/InCor


Files in This Item:
File Description SizeFormat 
art_MARANHAO_Lipoprotein_removal_mechanisms_and_aging_implications_for_the_2020.PDF
  Restricted Access
publishedVersion (English)210.72 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.